Does Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Have Gas After Even Less Sellers Involved?

October 12, 2017 - By Marie Mckinney

 Does Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Have Gas After Even Less Sellers Involved?

The stock of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) registered a decrease of 7.63% in short interest. ADMP’s total short interest was 3.15M shares in October as published by FINRA. Its down 7.63% from 3.41 million shares, reported previously. With 552,100 shares average volume, it will take short sellers 6 days to cover their ADMP’s short positions. The short interest to Adamis Pharmaceuticals Corporation’s float is 18.73%.

About 101,768 shares traded. Adamis Pharmaceuticals Corp (NASDAQ:ADMP) has declined 52.09% since October 12, 2016 and is downtrending. It has underperformed by 68.79% the S&P500.

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The company has market cap of $161.46 million. The Firm is engaged in the development of its specialty pharmaceutical products. It currently has negative earnings. The Firm is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company .

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) Ratings Coverage

Among 3 analysts covering Adamis Pharma (NASDAQ:ADMP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharma had 7 analyst reports since December 1, 2015 according to SRatingsIntel. The stock has “Buy” rating by Maxim Group on Monday, August 21. The firm earned “Buy” rating on Tuesday, December 1 by Maxim Group. Maxim Group maintained it with “Buy” rating and $1000 target in Monday, June 12 report. The firm has “Buy” rating given on Thursday, July 21 by Maxim Group. On Tuesday, September 12 the stock rating was initiated by Raymond James with “Buy”.

More recent Adamis Pharmaceuticals Corp (NASDAQ:ADMP) news were published by: Seekingalpha.com which released: “Adamis Pharmaceuticals: Updates To Thesis” on August 26, 2017. Also Seekingalpha.com published the news titled: “Adamis Pharmaceuticals: Strong Buy Before Huge Potential Catalyst” on June 01, 2017. Prnewswire.com‘s news article titled: “Stock Performance Review on Drug Delivery Industry — Adamis Pharma, Alkermes …” with publication date: October 05, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.